Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Naloxegol
Introduction
Overview
Overview
Naloxegol (INN; NKTR-118), or PEGylated naloxol,[1] trade name Movantik, is a peripherally–selective opioid antagonist under development by AstraZeneca, licensed from Nektar, for the treatment of opioid-induced constipation.[2]
References
References
- ↑ Roland Seifert; Thomas Wieland; Raimund Mannhold (17 July 2006). G Protein-Coupled Receptors as Drug Targets: Analysis of Activation and Constitutive Activity. John Wiley & Sons. p. 227. ISBN 978-3-527-60695-5. Retrieved 14 May 2012. Unknown parameter
|coauthors=ignored (help) - ↑ “Nektar | R&D Pipeline | Products in Development | CNS/Pain | Oral Naloxegol (NKTR-118) and Oral NKTR-119”. Retrieved 2012-05-14.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]